BioSpace News Archive

Akari Therapeutics, Plc today announced its financial results for the second quarter of 2021, as well as recent clinical progress.

Leap Therapeutics, Inc. today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock

Kleiner Device Labs today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) market clearance for its KG™2 Surge™ flow-thru interbody system.

The trial is being conducted with Jennifer Miller, M.D., from the University of Florida and will evaluate the Company’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.

A report by Heru Inc., the innovative vision diagnostics and augmentation leader, indicates that visual field test results from its wearable platform, re:Vive by Heru, are strongly correlated to the ZEISS Humphrey Field Analyzer (HFA).

Hexagon Bio today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.

Muno-Vax has created a suite of products that utilize a potent immuno-modulator to maximize the effectiveness of the immune system.

Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present at the 2021 Cantor Virtual Global Healthcare Conference.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that the TSX Venture Exchange has accepted the Company’s Notice of Intention to implement a normal course issuer bid.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference.